Evaluation of Sch 29,482 in the eradication of Neisseria meningitidis from nasopharyngeal carriers.
Fifty-eight chronic carriers of Neisseria meningitidis were given 250 mg of Sch 29,482 or placebo orally every 6 h for 4 days. Although 22 of 29 subjects taking Sch 29,482 became culture negative while taking the drug, only five were culture negative 2 weeks posttherapy. There were no significant adverse reactions.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D006801:Humans; D007769:Lactams; D008297:Male; D008585:Meningitis, Meningococcal / Q000188:drug therapy*; D009305:Nasopharynx / Q000382:microbiology*; D011897:Random Allocation
D000900:Anti-Bacterial Agents; D007769:Lactams; C033922:Sch 29482